SG11201607734PA - Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof - Google Patents
Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereofInfo
- Publication number
- SG11201607734PA SG11201607734PA SG11201607734PA SG11201607734PA SG11201607734PA SG 11201607734P A SG11201607734P A SG 11201607734PA SG 11201607734P A SG11201607734P A SG 11201607734PA SG 11201607734P A SG11201607734P A SG 11201607734PA SG 11201607734P A SG11201607734P A SG 11201607734PA
- Authority
- SG
- Singapore
- Prior art keywords
- artemisinin
- prevention
- derivatives
- treatment
- seborrheic keratosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166277 | 2014-04-28 | ||
| PCT/EP2015/059104 WO2015165856A1 (en) | 2014-04-28 | 2015-04-27 | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607734PA true SG11201607734PA (en) | 2016-11-29 |
Family
ID=50624467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607734PA SG11201607734PA (en) | 2014-04-28 | 2015-04-27 | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9907782B2 (en) |
| EP (1) | EP3137052B1 (en) |
| JP (1) | JP6487459B2 (en) |
| KR (1) | KR20160145818A (en) |
| CN (1) | CN106456600B (en) |
| AU (1) | AU2015252207B2 (en) |
| BR (1) | BR112016024916A2 (en) |
| CA (1) | CA2945646C (en) |
| DK (1) | DK3137052T3 (en) |
| ES (1) | ES2694623T3 (en) |
| HR (1) | HRP20181981T1 (en) |
| IL (1) | IL247909A0 (en) |
| MX (1) | MX367732B (en) |
| PL (1) | PL3137052T3 (en) |
| PT (1) | PT3137052T (en) |
| RU (1) | RU2702347C2 (en) |
| SG (1) | SG11201607734PA (en) |
| SI (1) | SI3137052T1 (en) |
| WO (1) | WO2015165856A1 (en) |
| ZA (1) | ZA201606837B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112823789B (en) * | 2019-11-19 | 2024-05-10 | 强生外科视力公司 | Compositions and methods for treating eyes |
| WO2024112391A1 (en) * | 2022-11-23 | 2024-05-30 | Timber Pharmaceuticals, Inc. | Compositions for local delivery of drug actives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2712861C2 (en) | 1977-03-21 | 1986-02-27 | Schering AG, 1000 Berlin und 4709 Bergkamen | 17-acetoxy-6-chloro-15β-hydroxy-1α, 2α-methylene-4,6-pregnadiene-3,20-dione, process for its preparation and medicament containing it |
| US4916204A (en) * | 1987-07-31 | 1990-04-10 | Massachusetts Institute Of Technology | Pure polyanhydride from dicarboxylic acid and coupling agent |
| JPH03170422A (en) | 1989-11-22 | 1991-07-24 | Dermatologic Res Corp | Treatment of skin disease |
| US7381427B2 (en) | 2001-02-09 | 2008-06-03 | Mickey Miller | Seborrheic keratosis treatment |
| CA2546210A1 (en) * | 2003-11-19 | 2005-06-02 | Vecta Ltd. | Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds |
| RU2423974C2 (en) | 2005-10-20 | 2011-07-20 | ЭПИФАРМ ГмбХ | Treatment and prevention of benign nevus pigmentosis (nevuses) by means of artemisinin and its derivatives |
| US8193376B2 (en) * | 2007-01-01 | 2012-06-05 | Bioderm Research | Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals |
| KR100795515B1 (en) * | 2007-01-11 | 2008-01-16 | 바이오스펙트럼 주식회사 | Composition for skin whitening comprising artemisinine |
| WO2009033494A1 (en) * | 2007-09-10 | 2009-03-19 | Dafra Pharma N.V. | 1- or 2-substituted artemisinin derivatives for increasing the in vivo biological activity of biologically active compounds |
| US9402823B2 (en) | 2010-12-17 | 2016-08-02 | Leo Laboratories Limited | Ingenols for treating seborrheic keratosis |
| KR20120085953A (en) | 2011-01-25 | 2012-08-02 | 원영두 | Cosmetics and Its Manufacturing Method |
| US9814659B2 (en) * | 2012-04-02 | 2017-11-14 | Johnson & Johnson Consumer Inc. | Methods of lightening the skin |
-
2015
- 2015-04-27 EP EP15717920.1A patent/EP3137052B1/en active Active
- 2015-04-27 RU RU2016146373A patent/RU2702347C2/en active
- 2015-04-27 SG SG11201607734PA patent/SG11201607734PA/en unknown
- 2015-04-27 KR KR1020167033065A patent/KR20160145818A/en not_active Application Discontinuation
- 2015-04-27 PL PL15717920T patent/PL3137052T3/en unknown
- 2015-04-27 JP JP2016562748A patent/JP6487459B2/en active Active
- 2015-04-27 WO PCT/EP2015/059104 patent/WO2015165856A1/en active Application Filing
- 2015-04-27 BR BR112016024916A patent/BR112016024916A2/en not_active Application Discontinuation
- 2015-04-27 PT PT15717920T patent/PT3137052T/en unknown
- 2015-04-27 CN CN201580022768.1A patent/CN106456600B/en active Active
- 2015-04-27 MX MX2016013114A patent/MX367732B/en active IP Right Grant
- 2015-04-27 ES ES15717920.1T patent/ES2694623T3/en active Active
- 2015-04-27 AU AU2015252207A patent/AU2015252207B2/en active Active
- 2015-04-27 CA CA2945646A patent/CA2945646C/en active Active
- 2015-04-27 US US15/305,516 patent/US9907782B2/en active Active
- 2015-04-27 DK DK15717920.1T patent/DK3137052T3/en active
- 2015-04-27 SI SI201530505T patent/SI3137052T1/en unknown
-
2016
- 2016-09-19 IL IL247909A patent/IL247909A0/en active IP Right Grant
- 2016-10-05 ZA ZA2016/06837A patent/ZA201606837B/en unknown
-
2018
- 2018-11-27 HR HRP20181981TT patent/HRP20181981T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20181981T1 (en) | 2019-01-25 |
| US9907782B2 (en) | 2018-03-06 |
| AU2015252207B2 (en) | 2019-09-12 |
| SI3137052T1 (en) | 2019-01-31 |
| EP3137052B1 (en) | 2018-08-29 |
| RU2016146373A (en) | 2018-05-28 |
| AU2015252207A1 (en) | 2016-10-06 |
| EP3137052A1 (en) | 2017-03-08 |
| KR20160145818A (en) | 2016-12-20 |
| JP2017516761A (en) | 2017-06-22 |
| PL3137052T3 (en) | 2019-02-28 |
| NZ724402A (en) | 2020-11-27 |
| US20170035727A1 (en) | 2017-02-09 |
| MX2016013114A (en) | 2017-02-14 |
| PT3137052T (en) | 2018-11-30 |
| IL247909A0 (en) | 2016-11-30 |
| CN106456600B (en) | 2020-08-04 |
| JP6487459B2 (en) | 2019-03-20 |
| ZA201606837B (en) | 2022-05-25 |
| CA2945646C (en) | 2020-12-15 |
| CA2945646A1 (en) | 2015-11-05 |
| DK3137052T3 (en) | 2019-01-02 |
| ES2694623T3 (en) | 2018-12-26 |
| RU2702347C2 (en) | 2019-10-08 |
| RU2016146373A3 (en) | 2018-11-14 |
| WO2015165856A1 (en) | 2015-11-05 |
| MX367732B (en) | 2019-09-04 |
| CN106456600A (en) | 2017-02-22 |
| BR112016024916A2 (en) | 2017-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281793A (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL252839A0 (en) | Treatment of pemphigus | |
| HK1253049A1 (en) | Glycan-interacting compounds and methods of use | |
| ZA201605639B (en) | Hppd variants and methods of use | |
| PL3157511T3 (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL251988A0 (en) | Glycan-interacting compounds and methods of use | |
| GB201701673D0 (en) | Methods of well treatment | |
| ZA201606243B (en) | Hppd variants and methods of use | |
| SI3089971T1 (en) | Compounds and methods of use | |
| IL290855A (en) | Methods of vitamin d treatment | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201413530D0 (en) | Treatment and prevention of malaria | |
| ZA201606450B (en) | Compounds and their methods of use | |
| PL3183003T3 (en) | Methods for prevention and/or treatment of infection | |
| HRP20181981T1 (en) | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof | |
| HK1246271A1 (en) | Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| GB201512139D0 (en) | Methods of treatment | |
| EP3104940A4 (en) | Compositions and methods for the prevention and/or treatment of schistosomiasis | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201522828D0 (en) | Prevention and treatment of glaucoma | |
| EP3188744A4 (en) | Methods for treatment and prevention of vascular disease |